Marginal zone B-cell lymphoma of the conjunctiva

Andrés J M Ferreri, Silvia Govi, Antonio Giordano Resti, Giulio Modorati, Riccardo Dolcetti, Annalisa Colucci

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lymphomas are the most common orbital malignancies, marginal zone B-cell lymphoma being the most common histotype. One quarter of these lymphomas exhibit conjunctival involvement, which is almost exclusively observed in indolent lymphomas (96% of conjunctival lymphomas). Primary conjunctival marginal zone B-cell lymphoma exhibits interesting and peculiar features, with some molecular, biological, clinical and prognostic differences from the rest of the ocular adnexal lymphomas. Recent studies demonstrate that chromosomal abnormalities, autoimmune disorders and infectious agents are variably associated with the development and behavior of this lymphoma. Conjunctival lymphomas are rarely lethal tumors and, in selected cases, may be managed without anti-tumor treatment. In other cases, conjunctival lymphomas cause symptoms that require immediate treatment. To date, no guidelines for the management of patients with conjunctival lymphoma exist. Surgical resection, radiotherapy and chemotherapy are the most common approaches to these malignancies, but the use of systemic immunotherapy, bacteria-eradicating antibiotic therapy and local treatments, such as intralesional injections of interferon or rituximab and eyedrops of cytostatics, is progressively growing.

Original languageEnglish
Pages (from-to)177-188
Number of pages12
JournalExpert Review of Ophthalmology
Volume5
Issue number2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Marginal Zone B-Cell Lymphoma
Conjunctiva
Tumors
Lymphoma
Cells
Interferons
Chemotherapy
Radiotherapy
Antibiotics
Bacteria
Neoplasms
Intralesional Injections
Ophthalmic Solutions
Cytostatic Agents
Therapeutics
Chromosome Aberrations
Immunotherapy
Guidelines
Anti-Bacterial Agents
Drug Therapy

Keywords

  • Chlamydophila psittaci
  • Conjunctival MALT lymphoma
  • MALT
  • Rituximab

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Marginal zone B-cell lymphoma of the conjunctiva. / Ferreri, Andrés J M; Govi, Silvia; Resti, Antonio Giordano; Modorati, Giulio; Dolcetti, Riccardo; Colucci, Annalisa.

In: Expert Review of Ophthalmology, Vol. 5, No. 2, 04.2010, p. 177-188.

Research output: Contribution to journalArticle

Ferreri, Andrés J M ; Govi, Silvia ; Resti, Antonio Giordano ; Modorati, Giulio ; Dolcetti, Riccardo ; Colucci, Annalisa. / Marginal zone B-cell lymphoma of the conjunctiva. In: Expert Review of Ophthalmology. 2010 ; Vol. 5, No. 2. pp. 177-188.
@article{f91160f0dc114444b6ac67e04a65a4f0,
title = "Marginal zone B-cell lymphoma of the conjunctiva",
abstract = "Lymphomas are the most common orbital malignancies, marginal zone B-cell lymphoma being the most common histotype. One quarter of these lymphomas exhibit conjunctival involvement, which is almost exclusively observed in indolent lymphomas (96{\%} of conjunctival lymphomas). Primary conjunctival marginal zone B-cell lymphoma exhibits interesting and peculiar features, with some molecular, biological, clinical and prognostic differences from the rest of the ocular adnexal lymphomas. Recent studies demonstrate that chromosomal abnormalities, autoimmune disorders and infectious agents are variably associated with the development and behavior of this lymphoma. Conjunctival lymphomas are rarely lethal tumors and, in selected cases, may be managed without anti-tumor treatment. In other cases, conjunctival lymphomas cause symptoms that require immediate treatment. To date, no guidelines for the management of patients with conjunctival lymphoma exist. Surgical resection, radiotherapy and chemotherapy are the most common approaches to these malignancies, but the use of systemic immunotherapy, bacteria-eradicating antibiotic therapy and local treatments, such as intralesional injections of interferon or rituximab and eyedrops of cytostatics, is progressively growing.",
keywords = "Chlamydophila psittaci, Conjunctival MALT lymphoma, MALT, Rituximab",
author = "Ferreri, {Andr{\'e}s J M} and Silvia Govi and Resti, {Antonio Giordano} and Giulio Modorati and Riccardo Dolcetti and Annalisa Colucci",
year = "2010",
month = "4",
doi = "10.1586/eop.10.11",
language = "English",
volume = "5",
pages = "177--188",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Marginal zone B-cell lymphoma of the conjunctiva

AU - Ferreri, Andrés J M

AU - Govi, Silvia

AU - Resti, Antonio Giordano

AU - Modorati, Giulio

AU - Dolcetti, Riccardo

AU - Colucci, Annalisa

PY - 2010/4

Y1 - 2010/4

N2 - Lymphomas are the most common orbital malignancies, marginal zone B-cell lymphoma being the most common histotype. One quarter of these lymphomas exhibit conjunctival involvement, which is almost exclusively observed in indolent lymphomas (96% of conjunctival lymphomas). Primary conjunctival marginal zone B-cell lymphoma exhibits interesting and peculiar features, with some molecular, biological, clinical and prognostic differences from the rest of the ocular adnexal lymphomas. Recent studies demonstrate that chromosomal abnormalities, autoimmune disorders and infectious agents are variably associated with the development and behavior of this lymphoma. Conjunctival lymphomas are rarely lethal tumors and, in selected cases, may be managed without anti-tumor treatment. In other cases, conjunctival lymphomas cause symptoms that require immediate treatment. To date, no guidelines for the management of patients with conjunctival lymphoma exist. Surgical resection, radiotherapy and chemotherapy are the most common approaches to these malignancies, but the use of systemic immunotherapy, bacteria-eradicating antibiotic therapy and local treatments, such as intralesional injections of interferon or rituximab and eyedrops of cytostatics, is progressively growing.

AB - Lymphomas are the most common orbital malignancies, marginal zone B-cell lymphoma being the most common histotype. One quarter of these lymphomas exhibit conjunctival involvement, which is almost exclusively observed in indolent lymphomas (96% of conjunctival lymphomas). Primary conjunctival marginal zone B-cell lymphoma exhibits interesting and peculiar features, with some molecular, biological, clinical and prognostic differences from the rest of the ocular adnexal lymphomas. Recent studies demonstrate that chromosomal abnormalities, autoimmune disorders and infectious agents are variably associated with the development and behavior of this lymphoma. Conjunctival lymphomas are rarely lethal tumors and, in selected cases, may be managed without anti-tumor treatment. In other cases, conjunctival lymphomas cause symptoms that require immediate treatment. To date, no guidelines for the management of patients with conjunctival lymphoma exist. Surgical resection, radiotherapy and chemotherapy are the most common approaches to these malignancies, but the use of systemic immunotherapy, bacteria-eradicating antibiotic therapy and local treatments, such as intralesional injections of interferon or rituximab and eyedrops of cytostatics, is progressively growing.

KW - Chlamydophila psittaci

KW - Conjunctival MALT lymphoma

KW - MALT

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=77951630141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951630141&partnerID=8YFLogxK

U2 - 10.1586/eop.10.11

DO - 10.1586/eop.10.11

M3 - Article

AN - SCOPUS:77951630141

VL - 5

SP - 177

EP - 188

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

SN - 1746-9899

IS - 2

ER -